Andrada Tarau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrada Tarau has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Sima
Second Department of Internal Medicine, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, Romania
3 shared publications - Ana Maria Mihai
Doctoral School, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania
3 shared publications - Florina Cristiana Lucaciu
Doctoral School, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania
3 shared publications - Ovidiu Rosca
Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, Victor Babeș University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
3 shared publications - Alexandra Bosoanca
Doctoral School, “Victor Babes” University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
2 shared publications - Madalina-Ianca Suba
Doctoral School, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania
2 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (7) , 1476
Viral Respiratory Infections and Host Immune Dynamics in Diabetes: Clinical Outcomes in the Post-COVID Era
The introduction of respiratory multiplex PCR in the post-pandemic world has improved the detection of viral infections, whose clinical relevance is still being characterized. Patients with diabetes mellitus (DM) exhibit altered innate immune responses, yet the effect of concurrent viral infection on their inflammatory trajectory and clinical outcomes remains poorly characterized. This study examined whether diabetes is associated with a more pronounced inflammatory response, delayed resolution, and worse multi-organ outcomes during viral respiratory infections. A prospective, longitudinal cohort of 430 hospitalized adults (DM: n = 211; non-DM: n = 219) with PCR-confirmed viral respiratory infections was stratified into four groups by diabetes and co-infection status using a respiratory multiplex PCR panel. Serum IL-6, CRP, NLR, procalcitonin, and urea were measured at admission (Day 1) and at clinical stabilization (Day 6). All variables failed normality testing (Shapiro–Wilk p < 0.0001); non-parametric methods were applied. Receiver operating characteristic (ROC) analysis was used to identify candidate biomarker cutoffs for mortality prediction. SARS-CoV-2 was the predominant pathogen (29.1%). In an exploratory comparison limited by small subgroup sizes (n = 8 vs. n = 14), co-infected diabetic patients had higher baseline inflammatory markers than co-infected non-diabetic patients: median IL-6 32.87 vs. 6.20 pg/mL (Mann–Whitney p = 0.0006) and median CRP 103.83 vs. 23.03 mg/L (p = 0.0012). At the Day 6 checkpoint, co-infected diabetic survivors had higher IL-6 (12.01 vs. 6.13 pg/mL, p = 0.0183) and showed little within-group NLR change (Wilcoxon p = 0.2367); these Day 6 estimates are subject to survivor selection and should be interpreted accordingly. In-hospital mortality was 25.6% in diabetic vs. 3.7% in non-diabetic patients (p < 0.0001). Diabetic patients more frequently required orotracheal intubation (6.4% vs. 1.0%, p = 0.0207) and high-flow nasal oxygen (HFNO) support (7.9% vs. 1.8%, p = 0.0166). In an internal ROC analysis, baseline IL-6 showed the highest discriminatory performance for in-hospital mortality (AUC 0.812, 95% CI 0.772–0.848), with a candidate cutoff of > 55.78 pg/mL (sensitivity 71.0%, specificity 79.1%); IL-6 outperformed CRP (AUC 0.706, DeLong p = 0.0029) and NLR (AUC 0.656, DeLong p = 0.0001). As this cutoff was derived and evaluated in the same cohort, it is reported as exploratory and requires external validation. In this single-center cohort, diabetes was associated with a more pronounced baseline inflammatory profile, slower resolution of the neutrophil-to-lymphocyte ratio, and greater multi-organ involvement during viral respiratory infection, including in the small co-infected subgroup. In the full cohort, diabetes remained associated with higher mortality, IL-6, and CRP after adjustment for age, sex, and BMI; however, the small co-infected subgroups could not be adjusted, so those specific comparisons should be regarded as hypothesis-generating and need confirmation in larger, adequately powered multi-center cohorts.
- 6 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (7) , 1476
Open AccessViral Respiratory Infections and Host Immune Dynamics in Diabetes: Clinical Outcomes in the Post-COVID Era
The introduction of respiratory multiplex PCR in the post-pandemic world has improved the detection of viral infections, whose clinical relevance is still being characterized. Patients with diabetes mellitus (DM) exhibit altered innate immune responses, yet the effect of concurrent viral infection on their inflammatory trajectory and clinical outcomes remains poorly characterized. This study examined whether diabetes is associated with a more pronounced inflammatory response, delayed resolution, and worse multi-organ outcomes during viral respiratory infections. A prospective, longitudinal cohort of 430 hospitalized adults (DM: n = 211; non-DM: n = 219) with PCR-confirmed viral respiratory infections was stratified into four groups by diabetes and co-infection status using a respiratory multiplex PCR panel. Serum IL-6, CRP, NLR, procalcitonin, and urea were measured at admission (Day 1) and at clinical stabilization (Day 6). All variables failed normality testing (Shapiro–Wilk p < 0.0001); non-parametric methods were applied. Receiver operating characteristic (ROC) analysis was used to identify candidate biomarker cutoffs for mortality prediction. SARS-CoV-2 was the predominant pathogen (29.1%). In an exploratory comparison limited by small subgroup sizes (n = 8 vs. n = 14), co-infected diabetic patients had higher baseline inflammatory markers than co-infected non-diabetic patients: median IL-6 32.87 vs. 6.20 pg/mL (Mann–Whitney p = 0.0006) and median CRP 103.83 vs. 23.03 mg/L (p = 0.0012). At the Day 6 checkpoint, co-infected diabetic survivors had higher IL-6 (12.01 vs. 6.13 pg/mL, p = 0.0183) and showed little within-group NLR change (Wilcoxon p = 0.2367); these Day 6 estimates are subject to survivor selection and should be interpreted accordingly. In-hospital mortality was 25.6% in diabetic vs. 3.7% in non-diabetic patients (p < 0.0001). Diabetic patients more frequently required orotracheal intubation (6.4% vs. 1.0%, p = 0.0207) and high-flow nasal oxygen (HFNO) support (7.9% vs. 1.8%, p = 0.0166). In an internal ROC analysis, baseline IL-6 showed the highest discriminatory performance for in-hospital mortality (AUC 0.812, 95% CI 0.772–0.848), with a candidate cutoff of > 55.78 pg/mL (sensitivity 71.0%, specificity 79.1%); IL-6 outperformed CRP (AUC 0.706, DeLong p = 0.0029) and NLR (AUC 0.656, DeLong p = 0.0001). As this cutoff was derived and evaluated in the same cohort, it is reported as exploratory and requires external validation. In this single-center cohort, diabetes was associated with a more pronounced baseline inflammatory profile, slower resolution of the neutrophil-to-lymphocyte ratio, and greater multi-organ involvement during viral respiratory infection, including in the small co-infected subgroup. In the full cohort, diabetes remained associated with higher mortality, IL-6, and CRP after adjustment for age, sex, and BMI; however, the small co-infected subgroups could not be adjusted, so those specific comparisons should be regarded as hypothesis-generating and need confirmation in larger, adequately powered multi-center cohorts.
- Open Access
- 30 June 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (7) , 654
Antibiotic Use, Bacterial Co-Infection, and Antimicrobial Resistance in Adults Hospitalized with COVID-19, Influenza, or RSV: A Systematic Review and Meta-Analysis
Background: Adults hospitalized with COVID-19, influenza A/B, or respiratory syncytial virus (RSV) frequently receive empirical antibiotics, but antibiotic prescribing, confirmed bacterial co-infection, antimicrobial resistance (AMR), and outcomes have not been jointly synthesized across these infections. Methods: We conducted a PRISMA 2020 systematic review and meta-analysis of 39 studies including 839,531 hospitalized adults. Random-effects models with Freeman–Tukey double-arcsine transformation pooled prevalence estimates; sensitivity and publication-bias analyses were performed where appropriate. Results: Pooled antibiotic use was 62.56% (95% CI, 53.75–70.97%) for COVID-19, 57.48% (25.76–86.09%) for influenza A/B, and 76.03% (67.62–83.53%) for RSV, with very high heterogeneity. Confirmed bacterial co-infection was lower: 5.31% (3.43–7.56%), 18.66% (9.98–29.30%), and 24.36% (18.53–30.70%), respectively. Prescribing-to-confirmed infection ratios ranged from 3.0 to 46.2. AMR evidence was restricted to COVID-19 studies and was dominated by carbapenem-resistant Gram-negative organisms, mainly in secondary, ICU-associated, or healthcare-associated infections. Confirmed bacterial complications were associated with ICU admission, longer hospitalization, and higher mortality. Conclusions: Antibiotic prescribing exceeded confirmed bacterial infection across all viral groups, but estimates require cautious interpretation due to heterogeneity, diagnostic uncertainty, observational evidence, and the absence of low-risk-of-bias studies. The evidence base was dominated by COVID-19 cohorts, while influenza A/B and RSV data, especially virus-specific AMR evidence, remain limited. COVID-19-specific AMR findings should not be generalized to influenza A/B or RSV. Virus-specific stewardship should prioritize rapid diagnostics, systematic sampling, reassessment, and de-escalation when bacterial infection is not confirmed.
- 30 June 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (7) , 654
Open AccessAntibiotic Use, Bacterial Co-Infection, and Antimicrobial Resistance in Adults Hospitalized with COVID-19, Influenza, or RSV: A Systematic Review and Meta-Analysis
Background: Adults hospitalized with COVID-19, influenza A/B, or respiratory syncytial virus (RSV) frequently receive empirical antibiotics, but antibiotic prescribing, confirmed bacterial co-infection, antimicrobial resistance (AMR), and outcomes have not been jointly synthesized across these infections. Methods: We conducted a PRISMA 2020 systematic review and meta-analysis of 39 studies including 839,531 hospitalized adults. Random-effects models with Freeman–Tukey double-arcsine transformation pooled prevalence estimates; sensitivity and publication-bias analyses were performed where appropriate. Results: Pooled antibiotic use was 62.56% (95% CI, 53.75–70.97%) for COVID-19, 57.48% (25.76–86.09%) for influenza A/B, and 76.03% (67.62–83.53%) for RSV, with very high heterogeneity. Confirmed bacterial co-infection was lower: 5.31% (3.43–7.56%), 18.66% (9.98–29.30%), and 24.36% (18.53–30.70%), respectively. Prescribing-to-confirmed infection ratios ranged from 3.0 to 46.2. AMR evidence was restricted to COVID-19 studies and was dominated by carbapenem-resistant Gram-negative organisms, mainly in secondary, ICU-associated, or healthcare-associated infections. Confirmed bacterial complications were associated with ICU admission, longer hospitalization, and higher mortality. Conclusions: Antibiotic prescribing exceeded confirmed bacterial infection across all viral groups, but estimates require cautious interpretation due to heterogeneity, diagnostic uncertainty, observational evidence, and the absence of low-risk-of-bias studies. The evidence base was dominated by COVID-19 cohorts, while influenza A/B and RSV data, especially virus-specific AMR evidence, remain limited. COVID-19-specific AMR findings should not be generalized to influenza A/B or RSV. Virus-specific stewardship should prioritize rapid diagnostics, systematic sampling, reassessment, and de-escalation when bacterial infection is not confirmed.
- Open Access
- 10 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 2890
Post-COVID Respiratory Sequelae in COPD: Mucus Plugging, Infectious Complications, and Risk-Stratified Follow-Up
Context/Objectives: In patients with COPD (chronic obstructive pulmonary disease), SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection represents an overlap of viral injury on a lung already affected by pathological mucus, altered mucociliary clearance, chronic inflammation, and impaired antiviral immunity. Methods: A focused narrative review (2020–2025) was conducted using clinical, experimental, and consensus evidence. The evidence was synthesized qualitatively, with priority given to cohort studies, meta-analyses, and mechanism-focused studies with clinical relevance. Results: Mucus obstruction (“mucus plugs”) is frequent in COPD (41–67%) and is associated with unfavorable outcomes. COPD also increases the risk of post-COVID respiratory sequelae. Bacterial coinfection at presentation is uncommon (3–5%), whereas secondary bacterial infections are more frequent (14–18%), especially in severe disease requiring intensive care, where VA-LRTI/VAP (ventilator-associated lower respiratory tract infection/ventilator-associated pneumonia) become predominant. Sepsis, whether viral or mixed, reflects disease severity and may contribute to functional decline and susceptibility to reinfections; however, the concept of a post-acute “sepsis legacy” in COPD after COVID-19 should currently be regarded as a clinically plausible but still emerging hypothesis rather than an established COPD-specific outcome. During recovery, acute exacerbation risk rises to 5.6% versus 3.9%, peaking in the first 30 days after severe disease (aHR ≈ 8.14). Persistent dyspnea and reduced DLCO (diffusing capacity for carbon monoxide) suggest ARDS-related injury, tissue remodeling, and microvascular dysfunction. Conclusions: In COPD, post-COVID respiratory sequelae result from the interaction of mucus, immunity, and infectious/sepsis-related complications. The first post-discharge month is a critical period requiring careful risk stratification and targeted follow-up.
- 10 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 2890
Open AccessPost-COVID Respiratory Sequelae in COPD: Mucus Plugging, Infectious Complications, and Risk-Stratified Follow-Up
Context/Objectives: In patients with COPD (chronic obstructive pulmonary disease), SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection represents an overlap of viral injury on a lung already affected by pathological mucus, altered mucociliary clearance, chronic inflammation, and impaired antiviral immunity. Methods: A focused narrative review (2020–2025) was conducted using clinical, experimental, and consensus evidence. The evidence was synthesized qualitatively, with priority given to cohort studies, meta-analyses, and mechanism-focused studies with clinical relevance. Results: Mucus obstruction (“mucus plugs”) is frequent in COPD (41–67%) and is associated with unfavorable outcomes. COPD also increases the risk of post-COVID respiratory sequelae. Bacterial coinfection at presentation is uncommon (3–5%), whereas secondary bacterial infections are more frequent (14–18%), especially in severe disease requiring intensive care, where VA-LRTI/VAP (ventilator-associated lower respiratory tract infection/ventilator-associated pneumonia) become predominant. Sepsis, whether viral or mixed, reflects disease severity and may contribute to functional decline and susceptibility to reinfections; however, the concept of a post-acute “sepsis legacy” in COPD after COVID-19 should currently be regarded as a clinically plausible but still emerging hypothesis rather than an established COPD-specific outcome. During recovery, acute exacerbation risk rises to 5.6% versus 3.9%, peaking in the first 30 days after severe disease (aHR ≈ 8.14). Persistent dyspnea and reduced DLCO (diffusing capacity for carbon monoxide) suggest ARDS-related injury, tissue remodeling, and microvascular dysfunction. Conclusions: In COPD, post-COVID respiratory sequelae result from the interaction of mucus, immunity, and infectious/sepsis-related complications. The first post-discharge month is a critical period requiring careful risk stratification and targeted follow-up.